跳至主要内容
临床试验/NCT06028126
NCT06028126
已完成
不适用

Efficacy of Intermittent Superficial Parasternal Intercostal Plane Block on Postoperative Pain Control in Patients Undergoing Cardiac Surgery With Median Sternotomy - EPOCH Randomized Clinical Trial

Unity Health Toronto5 个研究点 分布在 1 个国家目标入组 340 人2023年9月8日

概览

阶段
不适用
干预措施
Intermittent Superficial Parasternal Intercostal Plane Block - Experimental
疾病 / 适应症
Post-operative Pain
发起方
Unity Health Toronto
入组人数
340
试验地点
5
主要终点
Cumulative postoperative opioid use up to 72 hours
状态
已完成
最后更新
上个月

概览

简要总结

The goal of this clinical trial is to assess whether the use of intermittent superficial parasternal intercostal plane blocks reduces opioid usage in patients undergoing cardiac surgery with median sternotomy.

Participants randomized to the intervention group will receive the blocks with 0.2% ropivacaine administered via catheters placed in the superficial parasternal intercostal plane bilaterally under ultrasound guidance. Researchers will compare this group with a control group given 0.9% saline through similarly placed catheters. The primary outcome will be cumulative postoperative opioid use (measured as Milligram Morphine Equivalent (MME)) up to 72 hours following catheter insertion.

详细描述

This trial is comparing the use of 0.2% ropivacaine and 0.9% saline through a parasternal intercostal plane block and to measure whether there are any tangible changes in: 1. The primary outcome will be cumulative postoperative opioid use (measured as Milligram Morphine Equivalent (MME)) up to 72 hours following catheter insertion. Secondary outcomes will be: 2. cumulative postoperative opioid use from catheter insertion up to hospital discharge - measured as MME 3. median pain score - measured at rest and with coughing using a standardized numerical rating scale - for 72 hours post catheter insertion 4. delirium - assessed twice daily using institutional scores up to 72 hours following catheter insertion. 5.) Quality of Recovery -15 (QoR-15) score 24-96 hours post-surgery Tertiary outcomes will be: 6.) time from catheter insertion to extubation 7.) time from catheter insertion to first opioid analgesic provision following extubation 8.) time from catheter insertion to mobilization 9.) lengths of stay in the intensive care unit and the hospital 10.) postoperative nausea and vomiting - measured twice a day and antiemetic medication requirements for the 72 hours after catheter insertion 11.) opioid requirements following discharge from the hospital 12.) chronic post-sternotomy pain/disability (McGill Pain Questionnaire) 13.) participant-reported outcomes (PROMIS-29 survey) at 6 weeks and 3 months post surgery

注册库
clinicaltrials.gov
开始日期
2023年9月8日
结束日期
2026年3月4日
最后更新
上个月
研究类型
Interventional
研究设计
Parallel
性别
All

研究者

责任方
Sponsor

入排标准

入选标准

  • Adult patients undergoing cardiac surgery via median sternotomy

排除标准

  • Redo sternotomy, or cardiac surgery performed through non-sternotomy approaches (minimally invasive procedures, thoracotomies, mini-sternotomy, hemi-sternotomy, etc.)
  • Emergency procedures (surgery within 2 hours)
  • Clinical instability which in the judgement of the investigator precludes enrollment or participation in the study
  • Weight \< 50kg
  • Active systemic bacterial infection including infective endocarditis or pre-existing sternal infections
  • Surgery for infective endocarditis
  • Pregnancy or nursing
  • Chronic opioid/narcotic use \> 6 weeks, active use of illicit drugs, long-term opioid exposure or chronic pain disorder/syndromes
  • Allergies to amide anesthetic agents or any components of study interventions
  • Inability to comply with, or participate in, protocol (i.e. cognitive impairment/altered mental status/neurological deficit or disorder, inability to provide informed consent, inability to complete pain rating scales, etc.)

研究组 & 干预措施

0.2% ropivacaine

Intermittent superficial parasternal intercostal plane block via ultrasound-guided catheter placement. Initial bolus dosing of 20 milliliter (mL) of 0.2% ropivacaine per side after catheter placement, followed by intermittent boluses of 5 mL 0.2% ropivacaine per side every 3-4 hours. There will be a basal infusion rate of 0.1-1mL/hr per side.

干预措施: Intermittent Superficial Parasternal Intercostal Plane Block - Experimental

0.9% saline

Intermittent superficial parasternal intercostal plane block via ultrasound-guided catheter placement. Initial bolus dosing of 20 milliliter (mL) of placebo(0.9% saline) per side after catheter placement, followed by intermittent boluses of 5 mL placebo(0.9% saline) per side every 3-4 hours. There will be a basal infusion rate of 0.1-1mL/hr per side.

干预措施: Intermittent Superficial Parasternal Intercostal Plane Block - Placebo

结局指标

主要结局

Cumulative postoperative opioid use up to 72 hours

时间窗: 72 hours after catheter insertion.

Postoperative opioid use measured using Milligram Morphine Equivalent(MME) from catheter insertion up to 72 hours.

次要结局

  • Median pain score(over 72 hours post-extubation)
  • Cumulative post-operative opioid use(from time of catheter insertion until discharge from hospital)
  • Delirium(for 72 hours following catheter insertion)
  • Quality of Recovery-15 Scale(24-96 hours post surgery)
  • Cumulative post-operative opioid use(Average of 5 days.)

研究点 (5)

Loading locations...

相似试验